ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2741

Evidence That STAT3 controls NLRP3 inflammasome–dependent Release Of IL-1β and Pyronecrosis Through Regulation of mitochondrial activity

Jehad H. Edwan1, Jae Jin Chae2, Raphaela T. Goldbach-Mansky3 and Robert A. Colbert4, 1NIAMS NIH, Bethesda, MD, 2Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 4NIAMS/NIH, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Inflammasome activation and inflammation

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Self-activating NLRP3 mutations are responsible for cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID). Spontaneous inflammatory responses initiated by NLRP3 mutations promote inflammasome-mediated IL-1beta processing and release, and can induce a rapid cell death in a process known as pyronecrosis that is dependent on cathepsin B activation. Emerging evidence suggests a role for mitochondria in activation of the inflammasome, and mitochondrial STAT3 has been implicated in regulating cellular respiration. The aim of this study was to determine whether STAT3 is involved in IL-1b release and pyronecrosis. 

Methods: We used whole blood cells from NOMID and healthy donors, THP-1 cells with STAT3 expression knocked down, THP-1 cells with NLRP3 expression knocked down, and monocytes derived from NRLP3 deficient mice. Cells were stimulated with LPS in the presence of inhibitors of STAT3, followed by ATP. Cell supernatants were collected and incubated with IL-1beta-capturing beads. Cells were fixed and permeabilized. Then beads were added back to cells, and the mixture of cells with beads was stained with anti-IL-1beta, CD14, CD16, and CD83 antibodies and then evaluated by flow cytometry. LPS stimulated cells were also evaluated using immunofluorescent, electron microscopy and western blot analysis. In addition, cell metabolism pathways were analyzed using an XF extracellular flux analyzer.

Results: By flow analysis we found that a small population of monocytes, which undergoes pyronecrosis and is characterized by CD14hi/CD16low and intracellular CD83 expression, is responsible for the majority of IL-1beta production and release. Using confocal microscopy to visualize pyronecrosis, we provided and evidence that this process is NLRP3 dependent. Blockade of STAT3 function with inhibitors leads to complete inhibition of IL-1beta processing and release, as well as pyronecrosis in NOMID and ATP-stimulated healthy donor monocytes and in THP-1 cells. Similarly, STAT3 knockdown in THP-1 cells significantly inhibited IL-1beta release and pyronecrosis. Enhancement of the mitochondrial membrane potential in STAT3 knockdown cells bypasses the effect of STAT3 knockdown, and leads to increased IL-1beta processing and release, which was reversed with inhibitors of oxidative phosphorylation and glycolysis.

Conclusion: Taken together, these data suggest a previously unrecognized role for mitochondrial STAT3 in mediating NLRP3 effects on pyronecrosis and IL-1beta release, and provide a novel therapeutic target for NOMID and other NRLP3-mediated inflammatory diseases.


Disclosure:

J. H. Edwan,
None;

J. J. Chae,
None;

R. T. Goldbach-Mansky,
None;

R. A. Colbert,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-that-stat3-controls-nlrp3-inflammasome-dependent-release-of-il-1%ce%b2-and-pyronecrosis-through-regulation-of-mitochondrial-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology